Ono Pharmaceutical Co., Ltd.

Yoshifumi Kagamiishi

Kazuyuki Ohmoto

Hisao Nakai

Masashi Kato

Junichiro Manako

Tetsuji Saito

Tetsuo Obitsu

Rika Shinagawa

Taiji Shimoda

Masashi c/o Ono Pharmaceutical Co Ltd Kato

Junichiro c/o Ono Pharmaceutical Co Ltd Manako

[Problem to be solved] Provision of an agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the same. [Means for solving the problems] An agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the same, which comprises (2R)-2-propyloctanoic acid or a salt thereof. The agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the same, which comprises (2R)-2-propyloctanoic acid or a salt thereof, can be safely administered to patients of, for example, functional brain diseases such as depression, menopausal mood disorder, perimenopausal mood disorder, panic disorder, irritable bowel syndrome, social anxiety disorder, post-traumatic stress disorder or the like, and also can show excellent effects.

(2R)-2-propyloctanoic acid for functional brain disease

The present invention relates to the compound represented by formula (I): (wherein, all the symbols have the same meaning as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially a digestive system disease caused by stress and is superior to oral absorption.

Tricyclic compound and use thereof

A compound of a formula (I): wherein Rrepresents a C3-10 branched alkyl group which may be substituted; Rrepresents a hydrogen atom or a C1-4 alkyl group which may be substituted; Rrepresents a C1-4 alkyl group which may be substituted or a halogen atom; Rrepresents a C1-4 alkyl group which may be substituted; and ring 1 represents a cyclic group which has planarity and may have a substituent group, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof, is useful as a medicinal component having CRF antagonistic activity for the prevention and/or treatment of a neuropsychiatric disease, a peripheral organ disease and the like.

Bicyclic heterocyclic compound

The present invention relates to the compound represented by formula (I): (wherein, all the symbols has the same meanings as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially a digestive system disease caused by stress and is superior to oral absorption.

Tri-heterocyclic compound of formula (I) wherein each of W, X and Y is carbon or nitrogen; each of U and Z is CR, NR, nitrogen, oxygen, sulfur etc.; A ring is carbocyclic ring, heterocyclic ring; Ris alkyl, alkenyl, alkynyl, NRR, ORetc.; Ris carbocyclic ring, heterocyclic ring;and a pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical comprising them as an active ingredient. A compound of formula (I) is useful, in order to possess corticotropin releasing factor receptor antagonistic activity, for the prevention and/or treatment of depression, anxiety, eating disorder, posttraumatic stress disorder, peptic ulcer, irritable bowl syndrome, Alzheimer's disease, drug addiction or alcohol dependence syndrome etc.

Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient

Tri-heterocyclic compound of formula (I)wherein each of W, X and Y is carbon or nitrogen; each of U and Z is CR, NR, nitrogen, oxygen, sulfur etc.; A ring is carbocyclic ring, heterocyclic ring; Ris alkyl, alkenyl, alkynyl, NRR, ORetc.; Ris carbocyclic ring, heterocyclic ring;and a pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical comprising them as an active ingredient. A compound of formula (I) is useful, in order to possess corticotropin releasing factor receptor antagonistic activity, for the prevention and/or treatment of depression, anxiety, eating disorder, posttraumatic stress disorder, peptic ulcer, irritable bowl syndrome, Alzheimer's disease, drug addiction or alcohol dependence syndrome etc.

Growing community of inventors

Osaka, Japan

Yoshifumi Kagamiishi